Matthew J Sale
Overview
Explore the profile of Matthew J Sale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whaby M, Ketavarapu G, Koide A, Mazzei M, Mintoo M, Glasser E, et al.
Oncogene
. 2024 Oct;
43(48):3489-3497.
PMID: 39379700
The RAS family GTPases are the most frequently mutated oncogene family in human cancers. Activating mutations in either of the three RAS isoforms (HRAS, KRAS, or NRAS) are found in...
2.
Vasudevan H, Payne E, Delley C, Liu S, Mirchia K, Sale M, et al.
Nat Commun
. 2024 Jan;
15(1):477.
PMID: 38216572
Schwann cell tumors are the most common cancers of the peripheral nervous system and can arise in patients with neurofibromatosis type-1 (NF-1) or neurofibromatosis type-2 (NF-2). Functional interactions between NF1...
3.
Cuevas-Navarro A, Wagner M, Van R, Swain M, Mo S, Columbus J, et al.
Sci Adv
. 2023 Jul;
9(28):eadf4766.
PMID: 37450595
RIT1 is a RAS guanosine triphosphatase (GTPase) that regulates different aspects of signal transduction and is mutated in lung cancer, leukemia, and in the germline of individuals with Noonan syndrome....
4.
Lopez J, Bonsor D, Sale M, Urisman A, Mehalko J, Cabanski-Dunning M, et al.
J Biol Chem
. 2023 May;
299(6):104789.
PMID: 37149146
Sprouty-related EVH-1 domain-containing (SPRED) proteins are a family of proteins that negatively regulate the RAS-Mitogen-Activated Protein Kinase (MAPK) pathway, which is involved in the regulation of the mitogenic response and...
5.
Balmanno K, Kidger A, Byrne D, Sale M, Nassman N, Eyers P, et al.
Biochem J
. 2023 Apr;
480(9):587-605.
PMID: 37018014
Innate or acquired resistance to small molecule BRAF or MEK1/2 inhibitors (BRAFi or MEKi) typically arises through mechanisms that sustain or reinstate ERK1/2 activation. This has led to the development...
6.
Young L, Goldstein de Salazar R, Han S, Huang Z, Merk A, Drew M, et al.
Proc Natl Acad Sci U S A
. 2023 Jan;
120(5):e2208960120.
PMID: 36689660
The majority of pathogenic mutations in the neurofibromatosis type I () gene reduce total neurofibromin protein expression through premature truncation or microdeletion, but it is less well understood how loss-of-function...
7.
Sale M, Balmanno K, Cook S
Cancer Drug Resist
. 2022 May;
2(2):365-380.
PMID: 35582726
MEK1/2 inhibitors are clinically approved for the treatment of BRAF-mutant melanoma, where they are used in combination with BRAF inhibitors, and are undergoing evaluation in other malignancies. Acquired resistance to...
8.
Castel P, Dharmaiah S, Sale M, Messing S, Rizzuto G, Cuevas-Navarro A, et al.
Proc Natl Acad Sci U S A
. 2021 Aug;
118(33).
PMID: 34380736
RAS proteins are molecular switches that interact with effector proteins when bound to guanosine triphosphate, stimulating downstream signaling in response to multiple stimuli. Although several canonical downstream effectors have been...
9.
Winkler C, Armenia J, Jones G, Tobalina L, Sale M, Petreus T, et al.
Br J Cancer
. 2020 Dec;
124(5):951-962.
PMID: 33339894
Background: Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer...
10.
Sale M, Minihane E, Monks N, Gilley R, Richards F, Schifferli K, et al.
Nat Commun
. 2019 Nov;
10(1):5167.
PMID: 31727888
BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition is predominantly cytostatic, reflecting residual pro-survival...